Medicilon was selected into the first batch of Shanghai innovative enterprise headquarters

 On December 5, the awarding ceremony for the first batch of Shanghai innovative enterprise headquarters was held.  Zheng Gong, Deputy Secretary of the Shanghai Municipal Party Committee and Mayor, awarded plaques to 40 innovative enterprise headquarters and took a group photo.  Shanghai Medicilon Inc. (Medicilon) has become one of the first 10 biopharmaceutical companies selected as Shanghai's innovative enterprise headquarters.  This is the first time that Shanghai has independently recognized the headquarters of innovative enterprises, providing support to accelerate the development of Shanghai's innovative economy and build a technological innovation center with global influence.  This honor signifies that Medicilon's performance in technological innovation in new drug research and development has been highly recognized by the Shanghai Municipal Government.

The 40 innovative enterprise headquarters awarded licenses this time cover key industrial fields such as integrated circuits, biopharmaceutical, artificial intelligence, and digital economy.  It mainly presents the following characteristics:

One is strong leadership.  The licensed companies are mainly leading companies and technological innovation leaders in their respective industries. More than 90% of the company's products and services rank among the top in domestic and global market shares, and have strong industry position.

Second is strong innovation ability.  Licensed companies invest heavily in R&D. More than 50% of them have Class I new drugs or “first-of-its-kind” products domestically or globally, and more than 10% of them have won national or local science and technology progress awards.

Third is high growth potential.  The licensing companies are all market entities with good development momentum in recent years.  In recent years, 22 companies have been listed globally, showing strong development vitality. More than 60% of the companies have achieved a compound growth rate of more than 30% in operating income in the past three years, achieving rapid growth.

Fourth is the distinct agglomeration development . The regional agglomeration effect of licensed enterprises is relatively consistent with the development positioning of strategic emerging industry clusters in each district.

In addition, all licensing companies have more than two branches or subsidiaries outside Shanghai. The Shanghai headquarters has complex and multiple functions such as management, settlement, and R&D.  Most companies have also achieved global layout.

As one of the first batch of innovative enterprise headquarters selected in Shanghai, Medicilon has focused on the field of pre-clinical research and development of biomedicine since its establishment in 2004, focusing on the needs of new drug research and development.  With its innovative R&D technology and hard-core R&D strength, Medicilon continues to empower the development of the biopharmaceutical industry by focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA, PROTAC, ADC, and bi/multispecific antibodies, which integrates a one-stop biopharmaceutical preclinical R&D service platform.

According to the "Shanghai Innovative Enterprise Headquarters Recognition and Reward Management Measurement" issued on February 22, 2023, Medicilon will subsequently enjoy a number of preferential policies such as financial support, talent introduction, and tax incentives provided by the Shanghai Municipal Government.  These will further help Medicilon to show more achievements in empowering the research and development of new drugs.

Being recognized as one of the first batch of innovative enterprise headquarters in Shanghai is not only an affirmation of Medicilon's efforts in empowering innovative drug research and development in the past nearly two decades, but also trust in the company's future development.  This honor will encourage Medicilon to continue to establish a hard technology moat and make greater contributions to promoting the innovation and development of biopharmaceutical in Shanghai and China.

About Innovative Enterprise Headquarters
In order to accelerate the development of Shanghai's innovative economy, the Shanghai Municipal Government encourages various innovative entities such as high-tech enterprises, specialized new enterprises, and corporate technology centers to further improve their capabilities, accelerate the creation of composite enterprise headquarters, and provide support for the construction of a technological innovation center with global influence.  The innovative enterprise headquarters focuses on key areas of strategic emerging industries, independently owns the core intellectual property rights of domestically and internationally influential products or services locally, and leads the industry in overall technical level and innovation capabilities, have important advantages and high growth in market competition, make an important contribution to local economic and social development or play a leading role, and have control or exercise management rights over their cross-regional branches or businesses).